Stocky turns companies like MEDISTIM ASA MEDISTIM ORD SHS into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Buy. 0OCD.L combines elite growth (89/100 Growth Compounder Score) with solid value characteristics (73/100), supported by a 24.7× forward multiple reflecting investor confidence. The primary risk is a thin financial buffer—the company lacks substantial cash reserves or balance-sheet cushion to absorb downturns, making execution and working-capital discipline critical. Leadership alignment (59/100) suggests founder incentives are partially but not fully locked to shareholder outcomes.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for MEDISTIM ASA MEDISTIM ORD SHS:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 76/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates MEDISTIM ASA MEDISTIM ORD SHS (0OCD.L) at 76/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Buy. 0OCD.L combines elite growth (89/100 Growth Compounder Score) with solid value characteristics (73/100), supported by a 24.7× forward multiple reflecting investor confidence. The primary risk is a thin financial buffer—the company lack
0OCD.L's current Stocky Verdict is 76/100, placing it in the "Buy" band. This composite combines a 89/100 Compounder score, 59/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for MEDISTIM ASA MEDISTIM ORD SHS yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
MEDISTIM ASA MEDISTIM ORD SHS scores 59/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
MEDISTIM ASA MEDISTIM ORD SHS's Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to MEDISTIM ASA MEDISTIM ORD SHS.
Sign up free and unlock the full analysis on 0OCD.L — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 0OCD.L in the app.
